活性氧
肝损伤
药理学
肝细胞
乙酰半胱氨酸
对乙酰氨基酚
炎症
过氧化氢酶
肝保护
医学
化学
解毒剂
戒毒(替代医学)
药品
免疫学
氧化应激
抗氧化剂
毒性
内科学
生物化学
病理
酶
谷胱甘肽
替代医学
体外
作者
Fangyuan Li,Yueping Qiu,Fan Xia,Heng Sun,Hongwei Liao,An Xie,Ji‐Young Lee,Peihua Lin,Min Wei,Yanfei Shao,Bo Yang,Qinjie Weng,Daishun Ling
出处
期刊:Nano Today
[Elsevier]
日期:2020-07-15
卷期号:35: 100925-100925
被引量:100
标识
DOI:10.1016/j.nantod.2020.100925
摘要
Drug-induced liver injury (DILI) is the predominant cause of acute liver failure in many countries, which is closely associated with reactive oxygen species (ROS) and inflammation. Although N-acetylcysteine (NAC) is presently the first-choice antidote for DILI, it often fails to benefit the late stage patients due to its narrow therapeutic time window. Herein, we report ceria nanozymes (CeNZs) that simultaneously scavenge reactive oxygen species and generate oxygen for the treatment of acetaminophen-induced liver injury (a typical form of DILI), enabling a prolonged therapeutic time window as compared to NAC. It is found that CeNZs can effectively scavenge ROS in impaired hepatocytes for detoxification. More importantly, CeNZs can generate abundant oxygen based on their catalase (CAT)-mimic activity, thus further alleviating hypoxia and specifically inhibiting the pro-inflammatory macrophages to relieve inflammation for a promoted hepatocyte regeneration of DILI, which is vital for the treatment of late stage DILI when there is already massive hepatocyte necrosis. The dual detoxification and inflammatory regulation by CeNZs for DILI treatment with relatively long therapeutic time window as compared to NAC, together with the revealed mechanism herein, suggesting the future clinical use of CeNZs for DILI treatment, especially for the late stage DILI treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI